Hemoptysis after taking gefitinib for advanced lung cancer should seek medical treatment in time, and change the treatment plan under doctor’s guidance, such as surgery to stop hemoptysis, changing targeted drugs, radiotherapy or chemotherapy. Gefitinib is an antitumor drug mainly used for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with sensitive mutation of EGFR gene, and also used for the treatment of locally advanced metastatic non-small cell lung cancer with previous chemotherapy failure. Common adverse reactions include diarrhea, rash, nausea, vomiting, anorexia, fever, and bleeding. If hemoptysis occurs after taking Gefitinib, seek medical advice promptly and change the treatment regimen under doctor’s guidance: 1. If a large amount of hemoptysis is caused by tumor invasion of blood vessels, it is necessary to stop hemoptysis through surgical way in time. 2. If the hemoptysis is small and can be stopped by oneself, the targeted drug should be changed or radiotherapy or chemotherapy should be chosen according to the doctor’s instruction. Early detection, early diagnosis and early treatment can improve the prognosis of lung cancer patients and reduce the adverse reactions of the disease, and early stage can be cured through active treatment. In the late stage, active treatment can alleviate the symptoms, improve the quality of life and prolong the survival period.